Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Takeda Pharmaceutical Ltd ADR
(NY:
TAK
)
13.57
-0.12 (-0.91%)
Streaming Delayed Price
Updated: 11:11 AM EDT, Jul 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Takeda Pharmaceutical Ltd ADR
< Previous
1
2
3
4
5
6
7
Next >
Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency
June 15, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda to Present Oncology Portfolio and Pipeline Data at the 2023 ASCO Annual Meeting and EHA Congress
May 26, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Pharmaceutical Ltd. (NYSE: TAK) Highlighted for Surprising Price Action
April 06, 2023
Via
Investor Brand Network
Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
May 25, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
U.S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
May 16, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Delivers Strong Revenue and Profit Growth in FY2022; Updated Capital Allocation Policy Reflects Deleveraging Progress and Confidence in Growth Outlook
May 11, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces FDA Acceptance of BLA Resubmission for Investigational Subcutaneous Administration of Entyvio® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
April 27, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Corza Medical Signs Definitive Agreement to Acquire Takeda's TachoSil Manufacturing Operations
April 26, 2023
From
Corza Medical Inc.
Via
GlobeNewswire
HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer
April 17, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Takeda Receives FDA Approval to Expand the Use of HYQVIA® to Treat Primary Immunodeficiency in Children
April 11, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
April 11, 2023
From
Centogene NV
Via
GlobeNewswire
Takeda Announces New U.S. Corporate Social Responsibility (CSR) Program Partners
April 03, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
March 30, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Takeda Announces Results From Phase 4 Vedolizumab Study in Patients With Chronic Pouchitis Published in New England Journal of Medicine
March 30, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
March 30, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
BioLife Plasma Services Opens its 200th Plasma Donation Center in the U.S.
March 27, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Price Growth & Yield: For That Magical Combo, Leave the U.S.
March 21, 2023
Three foreign stocks, Takeda Pharmaceutical, United Microelectronics, and Coca-Cola FEMSA are showing that magical combination of growth and yield.
Via
MarketBeat
Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque Psoriasis
March 18, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Pharmaceutical Co. Ltd. (NYSE: TAK) Sets New 52-Week High in Friday Session
March 17, 2023
Via
Investor Brand Network
HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China
March 14, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
February 18, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiary
February 08, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
U.S. FDA Approves Takeda’s TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older
February 03, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Reinforces Long-term Growth Through Pipeline Advancement and Two Targeted Acquisitions; Delivers Another Strong Quarter in FY2022 Q3
February 02, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China
January 23, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor
January 23, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Named Global Top Employer for Sixth Consecutive Year
January 16, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC
January 11, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
January 09, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces Favorable Phase 3 Safety and Efficacy Results of TAK-755 as Compared to Standard of Care in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
January 05, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.